- Home
- FIVE vs EXEL Comparison
FIVE vs EXEL Comparison
Compare FIVE & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVE | EXEL |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 11.7B |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FIVE | EXEL |
|---|---|---|
| Price | $212.19 | $41.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 21 |
| Target Price | ★ $190.89 | $46.45 |
| AVG Volume (30 Days) | 829.6K | ★ 2.7M |
| Earning Date | 03-18-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 2.17 | ★ 2.78 |
| Revenue | ★ $3,876,527,000.00 | $452,477,000.00 |
| Revenue This Year | $24.54 | $13.66 |
| Revenue Next Year | $10.81 | $13.73 |
| P/E Ratio | $97.78 | ★ $14.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.38 | $32.38 |
| 52 Week High | $229.33 | $48.74 |
Technical Indicators
Market Signals| Indicator | FIVE | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.74 | 44.19 |
| Support Level | $136.72 | $40.01 |
| Resistance Level | $229.33 | $44.15 |
| Average True Range (ATR) | 7.65 | 1.24 |
| MACD | -1.98 | -0.05 |
| Stochastic Oscillator | 19.75 | 33.27 |
Price Performance
Historical ComparisonAbout FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.